Schering Rebetron Adds First-Line Hepatitis C Indication, Warnings
Executive Summary
Schering-Plough Rebetron has added a previously untreated hepatitis C indication and warnings with FDA approval Dec. 9.
You may also be interested in...
Roche Pegasys/Copegus Monitoring For Severe Infections Advised By Cmte.
Hepatitis C patients receiving Roche's Pegasys/ Copegus should be actively monitored for hematologic abnormalities and infections, FDA's Antiviral Drugs Advisory Committee recommended Nov. 14
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011